Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78096 | 0.88 | PARP1 (0.58) | PARP1PRAP1 | |
| SCHEMBL78182 | 0.88 | PARP1 (0.58) | PARP1PRAP1 | |
| SCHEMBL77391 | 0.85 | PARP1 (0.75) | PARP1 | |
| SCHEMBL3353831 | 0.84 | PARP1 (0.71) | PARP1 | |
| SCHEMBL87093 | 0.84 | PARP1 (0.74) | PARP1 | |
| SCHEMBL77298 | 0.83 | PARP1 (0.83) | PARP1PRAP1 | |
| SCHEMBL8269390 | 0.83 | PARP1 (0.73) | PARP1 | |
| SCHEMBL3665158 | 0.81 | PARP1 (0.83) | PARP1PRAP1 | |
| SCHEMBL8269392 | 0.80 | PARP1 (0.61) | PARP1 | |
| SCHEMBL13495551 | 0.79 | PARP1 (0.57) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | PARP1 1973/4885PRAP1 2633/4885 |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | PARP1 1973/4885PRAP1 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.